Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Ophthalmic Epidemiol. 2021 Dec;28(6):533-539. doi: 10.1080/09286586.2021.1883675. Epub 2021 Feb 21.
: Stargardt disease (SD) is the most common juvenile macular degeneration and a leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this chronic condition entails a long-term financial burden on affected individuals. The economic costs of SD have not been characterized in detail, so we aimed to estimate the direct healthcare cost of SD.: Outpatient administrative claims data (2010-2014) for patients with SD were analyzed from the IBM® MarketScan® Commercial Claims and Encounters Database. Two comparison groups were selected: nonexudative age-related macular degeneration (AMD) and bilateral sensorineural hearing loss (SHL). Gross median payments per year of insurance coverage were calculated.: A total of 472,428 patients were analyzed (5,015 SD, 369,750 SHL and 97,663 AMD patients respectively). The payment per year of insurance coverage for SD (median: 105.58 USD, IQR: 50.53 USD-218.71 USD) was higher than that of SHL (median: 51.01 USD, IQR: 25.66 USD-121.66 USD, < .001) and AMD (median: 76.20 USD, IQR: 38.00 USD-164.86 USD, < .001). When adjusted for age, sex, year of first service, and type of benefit plan, the annual payment for SD was 47.83 USD higher than SHL ( < .001) and 17.34 USD higher than AMD ( < .001).: There is a significant direct healthcare cost associated with SD. The annual per-patient cost of SD was higher than SHL, another condition that causes sensory impairment in people of all ages, and nonexudative AMD which causes a similar pattern of visual loss that typically begins later in life. The total lifetime per-patient cost of SD may exceed that of nonexudative AMD.
: 斯塔加特病（SD）是最常见的青少年黄斑变性，也是儿童不可矫正失明的主要原因。这种慢性疾病的进行性和不可治愈性质给患者带来了长期的经济负担。SD 的经济成本尚未详细描述，因此我们旨在估计 SD 的直接医疗保健成本。: 从 IBM® MarketScan®商业索赔和遭遇数据库中分析了 2010-2014 年 SD 患者的门诊行政索赔数据。选择了两个对照组：非渗出性年龄相关性黄斑变性（AMD）和双侧感觉神经性听力损失（SHL）。计算了每年保险覆盖的总中位数支付额。: 共分析了 472428 名患者（分别为 5015 名 SD、369750 名 SHL 和 97663 名 AMD 患者）。SD 每年的保险覆盖支付额（中位数：105.58 美元，IQR：50.53 美元-218.71 美元）高于 SHL（中位数：51.01 美元，IQR：25.66 美元-121.66 美元，<0.001）和 AMD（中位数：76.20 美元，IQR：38.00 美元-164.86 美元，<0.001）。在调整年龄、性别、首次服务年度和福利计划类型后，SD 的年支付额比 SHL 高 47.83 美元（<0.001），比 AMD 高 17.34 美元（<0.001）。: SD 与显著的直接医疗保健成本相关。SD 每位患者的年治疗费用高于 SHL，后者是一种导致所有年龄段人群感觉障碍的疾病，也高于非渗出性 AMD，后者导致类似的视力丧失模式，通常在生命后期开始。SD 的每位患者终生总治疗费用可能超过非渗出性 AMD。
